OraSure受益于23andMe/Regeneron交易，股价上涨

2025-05-20 00:33

OraSure Technologies (NASDAQ:OSUR) is up ~6% Monday as it is seen as a beneficiary of Regeneron Pharmaceuticals' (NASDAQ:REGN) deal, announced earlier in the day, to purchase substantially all the assets of genetic testing company 23andMe.
OraSure, which is engaged in the manufacture of diagnostics tests, already claims Regeneron as a customer. That "should bode well for a continued relationship between OSUR and 23andMe," according to an Evercore ISI note.
Analyst Vijay Kumar, who rates OraSure at in line, said that the Regeneron/23andMe announcement "should remove the downside scenario where OSUR's 23andMe contribution will be 0 into perpetuity...Instead, we expect 23&Me should continue to be a meaningful customer going forward."
Evercore ISI estimates that 23andMe was a ~$13M customer in 2024
The $256M agreement between Regeneron and 23andMe was the result of a court-supervised sale process and auction.

More on OraSure Technologies